Patent intelligence · US
US 9422260
Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one(Rose Bengal) and related xanthenes
Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one(Rose Benga…
Patent details — US 9422260
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 23, 2016
- Expiration
- Aug 18, 2036
- Applicant
- Provectus Pharmatech, Inc.
- Claims
- 11
- CPC classes
- A61P, A61P1/00, A61P1/02, A61P11/00
Quick answer
US 9422260 (Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one(Rose Bengal) and related xanthenes) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Aug 23, 2016. Expires Aug 18, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Provectus Pharmatech, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61P, A61P1/00, A61P1/02, A61P11/00, A61P13/00, A61P15/00
More from Provectus Pharmatech, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377068
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 12133840
Halogenated xanthene composition and method for treating hematologic cancers
granted -
US 12064507
Composition and method for oral treatment of leukemia
granted -
US 11974980
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 11975106
Uses of halogenated xanthenes in oncology and virology
granted -
US 11938182
Halogenated xanthenes as vaccine adjuvants
granted -
US 11426379
Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
granted -
US 11419844
Halogenated xanthene composition and method for treating hematologic cancers
granted
Frequently asked questions
What is US patent 9422260?
US 9422260 (Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one(Rose Bengal) and related xanthenes) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Aug 23, 2016. Expires Aug 18, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9422260?
Provectus Pharmatech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.
When does US 9422260 expire?
Our index shows an expiration date of Aug 18, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.